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Chemotherapy is one of the most effective cancer treatments to date; however, it 
has the potential to produce debilitating life-long side effects. Chemotherapy-induced 
peripheral neuropathy is a side effect caused by toxic chemotherapy agents that 
deteriorate the peripheral nerves of the body. Research has suggested that aerobic and 
strength training may be able to alleviate some of the symptoms associated with 
chemotherapy-induced peripheral neuropathy. Some of the benefits of both aerobic and 
strength training include increasing blood and nutrient flow to the peripheral nerves, 
which could help restore sensation and alleviate the some symptoms of chemotherapy-
induced peripheral neuropathy. However, to our knowledge, there is little research 
evaluating the effects of an aerobic and strength-training intervention on chemotherapy-
induced peripheral neuropathy. Purpose: The purpose of this study was to examine the 
effects of a 12-week aerobic and strength training intervention on the symptoms of 
chemotherapy-induced peripheral neuropathy. Methods: Ten participants (aged 48-76) 
participated in a 12-week exercise intervention and completed a pre-, mid-, and post- 
4.17/1g Semmes Weinstein Monofilament Test and 5.07/10g Semmes Weinstein 
Monofilament Test. A comprehensive physical assessment was completed before and 






revealed significant (p < 0.05) changes from pre-, mid-, and post- 4.17/1g Semmes 
Weinstein Monofilament Test scores. However, there were no significant (p < 0.05) 
results detected with the 5.07 Semmes Weinstein Monofilament test.  Paired samples t-
tests revealed significant (p < 0.05) differences between aerobic and several strength tests 
from pre- to post-assessment. Several psychological scores improved significantly (p < 
0.05) as well from pre- to post- assessment. Conclusion: Significant improvements were 
observed for the 4.17/1g Semmes Weinstein Monofilament test following a 12-week 
aerobic and strength training intervention for subjects experiencing chemotherapy-
induced peripheral neuropathy. These results suggest that aerobic and strength training 
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The American Cancer Society estimates that there were 14.5 million Americans 
living with cancer in 2014 (American Cancer Society, 2015). Every year cancer rates 
continue to increase even with advances in modern medicine. The most common 
treatments for cancer include surgery, chemotherapy, radiation therapy, and hormone 
therapy. When diagnosed with cancer, chemotherapy is one of the effective forms of 
treatment that can prolong survival (Malik & Stillman, 2008). There are numerous types 
and combinations of chemotherapy treatments available; however, they all have the 
potential of producing debilitating side effects.  
 One of the major side effects of chemotherapy treatments is chemotherapy-
induced peripheral neuropathy (CIPN). Thirty to forty percent of all patients receiving 
chemotherapy will experience CIPN, which is a type of peripheral neuropathy that is 
caused by certain chemotherapy agents (Pignataro & Swisher, 2010). Peripheral 
neuropathy is defined as any damage that occurs to the peripheral nerves and enables 
them to function properly. Neuropathic symptoms include pain, numbness, tingling, 
decreased motor function, weakness, and any type of paresthesia or dysesthesia (Kluding 
et al., 2012; Pignataro & Swisher, 2010; Hausheer, Schilsky, Bain, Berghorn, & 
Lieberman, 2006; Kochman, Carnegie, & Burke, 2002). Several theories have suggested 





or carboplatin, pre-mature cell apoptosis may be occurring (Argyriou, Bruna, Marmiroli, 
& Cavaletti, 2012). It has been theorized that taxane chemotherapy drugs interfere with 
the microtubules of the mitotic spindle, which in turn interferes with axonal transport, 
thereby affecting the somatosensory neurons and causing destruction of distal nerve 
endings (Argyriou et al., 2012). Taxane chemotherapy has also been shown to disrupt 
Schwann cells, which leads to many issues within the axonal membranes, and can disrupt 
the myelination of the axon terminals (Quasthoff & Hartung, 2002; Persohn et al., 2005; 
Wickham, 2007). Platinum chemotherapies such as cisplatin, carboplatin, and oxaliplatin, 
have been shown to disrupt the cytoplasmic and nuclear components of an axon and 
disrupt axonal transport ultimately (Wickham, 2007).  The exact cause behind CIPN is 
still unknown; however, exercise may be a viable method to alleviate the symptoms.  
 Within the past ten years, exercise has shown to benefit cancer patients 
tremendously and reduce cancer-related side effects (Hsieh et al., 2008; Schneider, Hsieh, 
Sprod, Carter, & Hayward, 2007a; Schneider, Hsieh, Sprod, Carter, & Hayward, 2007b). 
Major cancer-related side effects include toxicities to major organ systems in the body 
along with fatigue, psychological issues, lymphedema, pain, body image problems, 
depression, anxiety, and sleep disturbances (Schneider et al., 2007a; Schneider et al., 
2007b; Schneider, Dennehy, & Carter, 2003). Some of the toxicities that present include 
immune system toxicity, cardiovascular toxicity, pulmonary toxicity, gastrointestinal 
toxicity, hepatic toxicity, neuroendocrine toxicity, nephrotoxicity, and dermatological 
toxicity (Schneider et al., 2003). Exercise has been shown to improve the cardiovascular 
system, respiratory system, metabolic system, neuromuscular system, and endocrine 





a reduction in chemotherapy-related side effects. However, very few studies have been 
conducted to examine the effects of exercise on CIPN.  
Previous research has theorized that strength training and aerobic training may 
help alleviate CIPN (Kluding et al., 2012; Tofthagen, Visovsky, & Berry, 2012). Kluding 
et al., (2012) found significant evidence that an aerobic and strength training intervention 
helped to reduce the pain and symptoms associated with diabetic peripheral neuropathy. 
Symptoms of CIPN are assessed in a variety of ways. Nerve conduction tests, Semmes 
Weinstein monofilament tests (SWMT), and the Michigan Neuropathy Screening 
Instrument (MNSI) are common ways to assess CIPN currently. However, there is no 
gold standard for assessing CIPN. Research has shown SWMT can be a beneficial 
instrument to assess CIPN over time using a composite score (Tan, 2010; Feng, 
Schlösser, & Sumpio, 2009; Kamei et al., 2005; Lee et al., 2003; Kochman et al., 2002; 
Olaleye, Perkins, & Bril, 2001; Kumar et al., 1991).  To date, no studies have evaluated 
the effects of an aerobic and strength training exercise intervention on CIPN.  
Statement of Purpose 
	  
The purpose of this study was to examine the effects of a 12-week aerobic and 




H Participants who are experiencing CIPN and participating in the strength 
training and aerobic training intervention will show improvements in 
CIPN symptoms. Potential improvements would translate to lower CIPN 








Significance of Study 
	  
Patients who have received chemotherapy treatment can potentially develop CIPN 
as a life-long side effect, which could lead to an overall decrease in quality of life if left 
untreated (Kluding et al., 2012; Pignataro & Swisher, 2010; Hausheer et al., 2006; 
Kochman et al., 2002). CIPN can decrease the quality of life for many patients and inhibit 
them from activities of daily living. Exercise has already shown to reduce chemotherapy-
related side effects for other major toxicities, and may potentially reduce CIPN symptoms 
(Schneider et al., 2007a; Schneider et al., 2003; Kluding et al., 2012; Tofthagen et al., 
2012). To date no research exists that evaluates the effects of strength training and 
aerobic training on the severity of CIPN. If in fact, exercise training regimens that include 
both aerobic and resistance components can alleviate CIPN, such interventions should be 











 Chemotherapy-Induced Peripheral Neuropathy can be described as damage to the 
peripheral nerves as a result of exposure to chemotherapy toxic agents. Every 
chemotherapeutic drug is unique and each drug can potentially damage peripheral nerves 
differently. Platinum drugs, taxanes, epothilones, vinca alkaloids, bortezomib, and 
thalidomide are the most common chemotherapeutic agents that cause CIPN (Wolf, 
Barton, Kottschade, Grothey, & Loprinzi, 2008; Hausheer et al., 2006). These toxic 
agents affect both small and large fiber axons (Wolf et al., 2008; Schloss et al., 2013; 
Kluding et al., 2012). Small fibre axons are unmyelinated and are responsible for sensing 
temperature and pain (Wolf et al., 2008; Schloss et al., 2013), while large fibre axons are 
myelinated and are responsible for sensing position, vibration, and motor control (Wolf et 
al., 2008; Schloss et al., 2013). While these drugs are unable to cross the blood brain 
barrier (Schloss et al., 2013) the peripheral nervous system does not have a protective 
barrier and it is susceptible to these agents.  
At the cellular level, platinum drugs may alter the DNA of peripheral nerve cells 
by causing an overproduction of cyclin D1 expression and hyper-phosphorylation of the 





(Argyriou et al., 2012). Another possibility is that there could be a disruption in 
mitochondrial function within the cells, which causes oxidative stress and triggers 
neuronal apoptosis (Argyriou et al., 2012).  Some platinum agents, specifically 
oxaliplatin, have been hypothesized to cause CIPN due to chelation of calcium from 
neural membranes (Hausheer et al., 2006). These could be possible mechanisms 
explaining CIPN with platinum based chemotherapy.  
Another major chemotherapy drug group, the taxane, causes a disruption in the 
microtubules of the mitotic spindle, which interferes with axonal transport in the axons as 
well as the soma of somatosensory neurons (Argyriou et al., 2012). It has also been 
observed that taxane drugs initiate death of the peripheral nerves, starting from the distal 
nerve endings and ultimately causing a disturbance of cytoplasmic flow within the neuron 
itself (Quasthoff & Hartung, 2002; Argyriou et al., 2012). Taxanes also have deleterious 
effects on excitability of sensory and motor nerves due to an axonal membrane leak and a 
non-specific ion influx (Quasthoff & Hartung 2002). In order for a membrane to 
depolarize correctly, the correct exchange of sodium and potassium must occur across the 
membrane. If ions are crossing the membrane in a disorderly fashion, problems may arise 
with message and cell signaling. Like taxane drugs, epothilones have a similar effect on 
the neuron.  Epothilones have been found to cause polymerization of the tubulin in 
microtubules in the absence of guanosine triphosphate, which is needed in a healthy cell 
to polymerize (Argyriou et al., 2012). The preformed tubulin is then put into 
depolymerizing conditions, which ultimately lead to the destruction of the microtubules 





The vinca alkaloids group of chemotherapy drugs includes vinblastine, 
vincristine, vinorelbine, and vinesine drugs (Hausheer et al., 2006). Vinca alkaloids 
ultimately lead to cell death due to an arrest of dividing cells during the metaphase stage 
of development (Argyriou et al., 2012).  The vinca alkaloids cause alterations in the 
neuronal cytoskeleton due to binding on the intracellular tubulin, which leads to 
alterations in axonal transport, buildup of neurofilaments in the cell bodies and proximal 
axons, and accumulation of axoplasmic organelles and vesicles (Quasthoff & Hartung 
2002; Argyriou et al., 2012). There is also a reduction in myelin thickness and shortening 
of inter-nodal length that occurs (Argyriou et al., 2012).  
 The pathogenesis of bortezomib and thalidomide are still unknown to researchers. 
Theories suggest that bortezomib interferes with transcription, nuclear processing, 
nuclear transport, and cytoplasmic translation of mRNA’s in dorsal root ganglion 
neurons. This can ultimately affect the signaling cascade within the neuron and can lead 
to cytotoxicity (Hausheer et al., 2006). Thalidomide is hypothesized to causes 
angiogenesis inhibition, immunomodulation, and cytokine modulation (Argyriou et al., 
2012). By inhibiting angiogenesis, the formation of new blood vessels, the body may be 
depriving itself of blood circulation starting with the peripheries first. Also, 
immunomodulation may be beneficial for some patients with cancer because it allows 
medical professionals to essentially modify the immune system, but it may be detrimental 
to the peripheral nerves. However, much research still needs to be performed to clearly 






Symptoms of Chemotherapy-Induced 
Peripheral Neuropathy 
 
The symptoms for CIPN are similar and have found to be dose-dependent across 
all chemotherapy drugs (Schloss et al., 2014; Wolf et al., 2008; Quasthoff & Hartung 
2002). This infers that higher cumulative doses of chemotherapy may result in longer and 
more severe CIPN.  This is detrimental to the patient because if the CIPN escalates, it can 
cause secession of the chemotherapy. Also, different chemotherapy drugs will elicit 
different symptoms of CIPN. Many CIPN patients complain of a “glove-and-stocking” 
feeling and distribution (Schloss et al., 2013). This can be best described as the patient 
feeling as if they are always wearing gloves and socks on their hands or feet. CIPN can 
also present as numbness, tingling, pain, decreased motor function, weakness, and any 
type of paresthesia or dysesthesia (Kluding et al., 2012; Hausheer et al., 2006; Kochman 
et al., 2002). Another symptom of CIPN is the inability to sense temperature (Wilkes, 
2007). It ultimately leads to a diminished quality of life, chronic discomfort, reduced 
physical activity, reduced dexterity, and in some cases ulceration, which can lead to 
amputation (Schloss et al., 2014; Speck et al., 2012; Feng et al., 2009; Lee et. al., 2003; 
Kumar et al., 1991). 
Chemotherapy-Induced  
Peripheral Neuropathy Testing 
 
 Currently there is no gold standard for the testing of CIPN. However, the Semmes 
Weinstein Monofilament Test (SWMT) has been shown to be a beneficial instrument for 
the testing of all peripheral neuropathy (Tan, 2010; Feng et al., 2009; Kamei et al., 2005; 
Lee et al., 2003; Kochman et al., 2002; Olaleye et al., 2001; Kumar et al., 1991). The 





The monofilament is applied to the surface of the skin and force is applied until the 
monofilament bends. The monofilament will buckle at a set force, which helps control for 
variability between tests and is reproducible (Feng et al., 2009; Kumar et al., 1991).  
These monofilaments can measure the subject’s cutaneous pressure perception threshold 
(Kumar et al., 1991). The 5.07/10 g SWMT is the most commonly used monofilament by 
clinicians and researchers, as the inability to sense this gauge suggests the loss of 
protective sensation and an increased risk of foot ulceration (Feng et al., 2009; Tan, 2010; 
Lee et al., 2003; Olaleye et al., 2001; Kamei et al., 2005; Leonard, Farooqi, & Myers, 
2004; Kumar et al., 1991). The 5.07/10g SWMT has been validated against nerve 
conduction tests and vibration perception threshold tests, and were all found to be 
correlated with each other (Feng et al., 2009; Kamei et al., 2005; Lee et al., 2003; Olaleye 
et al., 2001; Kumar et al., 1991). The 4.17/1g SWMT is commonly used alongside the 
5.07/10g SWMT due to its ability to detect a diminishing protective sensation (Lee et al., 
2003; Callahan, Hunter, & Mackin, 1995; Kumar et al., 1991). The 4.17/1g SWMT may 
be useful in the early detection of peripheral neuropathy. Due to the fact that very little 
research regarding CIPN has been conducted, many of the studies examined pertained to 
diabetic peripheral neuropathy. Therefore, these findings may be relevant for diabetic 
peripheral neuropathy, but CIPN may be more responsive to other testing instruments. 
 Similarly to the testing modality, there is no agreement over which sites and how 
many sites on the hands and feet should be tested. The first, third, and fifth metatarsal 
head have consistently been shown to be positive indicators of peripheral neuropathy, and 
have a 94% accuracy of identifying peripheral neuropathy (Tan, 2010; Lee et al., 2003).   





medial plantar nerves which innervate the first through third metatarsal head along the 
medial plantar aspect of the foot; 2) the lateral plantar nerve which innervates the fourth 
and fifth metatarsals along the lateral plantar aspect of the foot; 3) the saphenous nerve 
which innervates the arch of the foot; 4) the sural nerve which innervates the most lateral 
aspect of the foot; 5) the tibial nerve which innervates the calcaneus; 6) the deep peroneal 
nerve which innervates the majority of the dorsal surface of the foot; and 7) the deep 
peroneal nerve which innervates the dorsal surface of the foot in-between the first and 
second metatarsals (Tortora & Derrickson, 2009). In the hand: 1) the median nerve 
innervates the palmar surface of the first, second, third, and half of the fourth phalanges 
and metacarpals, 2) the ulnar nerve innervates half of the fourth phalange and 
metacarpal., as well as the fifth phalange and metacarpal, and 3) the radial nerve 
innervates the most lateral aspect of the first metacarpal (Tortora & Derrickson, 2009).  
Strength and Aerobic Training Benefits 
 in Chemotherapy-Induced 
Peripheral Neuropathy 
 
There is very little research regarding the effects of strength and aerobic training 
on peripheral neuropathy. Some studies have shown that exercise can improve balance, 
improve gait patterns, and decrease the risk of falls in neuropathic patients, yet 
neuropathic symptoms were not assessed over time (Tofthagen et al., 2012). One study 
did find that a 10-week exercise intervention improved a selected measure of peripheral 
nerve function (Kluding et al., 2012). Kluding et al., (2012) designed a 10-week exercise 
program consisting of aerobic and strength training exercises. The aerobic exercise was 
kept at a moderate level, 50%-70% of VO2 reserve, and strength training was performed 





modified Borg scale. Health professionals monitored the exercise and results were based 
on the Michigan Neuropathy Screening Instrument (MNSI). The MNSI is a survey 
conducted by a health professional that includes a lengthy physical assessment and a 
medical history section. However, this study presented major limitations including short 
intervention duration, small sample size, lack of a control group, and limited knowledge 
of CIPN (Kluding et al., 2012). Along with the cellular level disruptions chemotherapy 
agents can cause, they may also induce sensory or motor neuropathy by activating 
mitochondrial and vascular dysfunction (Tofthagen et al., 2012). However, research has 
supported the assumption that exercise stimulates endoneurial blood flow and 
mitochondrial protein synthesis and glycolysis which both have the ability to generate 
energy (Tofthagen et al., 2012). Aerobic exercise specifically has been shown to enhance 
axon regeneration after peripheral nerve injury (Sabatier, Redmon, Schwartz, & English, 
2008).  This could be due to an up regulation in neurotropic factors that occur with 
exercise and increased neuronal activity (Sabatier et al., 2008). Neurotropic factors are 
responsible for growth and maintenance of neurons within the body (Widmaier, Raff, & 
Strang, 2006). Strength exercise has also been thought to enhance nerve re-innervation 
(Wilkes, 2007). Exercise could ultimately increase the supply of blood, oxygen, and other 
essential nutrients to the mitochondria, and then to the peripheral nerves, which could 
result in fewer neuropathic symptoms (Tofthagen et al., 2012). Benefits of exercise on 
peripheral nerve damage have not received much attention in research. The lack of 
research in this area demonstrates a need for studies investigating the beneficial effects of 












The purpose of this study was to examine the effects of a 12-week aerobic and 
strength training intervention on the symptoms of chemotherapy-induced peripheral 
neuropathy.  This study consisted of a pre-to-posttest design. Pre and post physical 
assessments were conducted on each participant to establish whether a training effect and 
if any physiological improvements occurred. The pre and post assessments consisted of a 
neuropathy screening, physiological screenings, and psychological screenings. Baseline 
measurements were gathered prior to and following each individual exercise intervention. 
A peripheral neuropathy screening was performed prior to the intervention, at 6 weeks, 
and at 12-weeks to evaluate changes in chemotherapy-induced peripheral neuropathy 
(CIPN) symptoms.  
Preliminary Paperwork 
	  
 Before entering the RMCRI program and inclusion into the study, each participant 
was asked to complete questionnaires and surveys, which included a medical history, 
cancer history, and a lifestyle and activity evaluation. The cancer and medical history 
established pertinent information about cancer diagnosis, cancer stage, past and current 
treatments, pre-existing conditions, and limitations and considerations for exercise.  The 





as previous and current activity levels, tobacco use, alcohol use, and fluctuations in body 
weight. Psychological measures were evaluated using the Beck Depression Inventory 
(Salkind, 1969), the Piper Fatigue Scale (Piper et al., 1998), and the Ferrans and Powers 
Quality of Life Index Cancer Version III (Ferrans & Powers, 1985). Each participant was 
asked to complete surveys and questionnaires prior to each pre-and-post assessment. 
Participants  
	  
 Fifteen participants were recruited for this study.  Each cancer patient was 
referred to the Rocky Mountain Cancer Rehabilitation Institute (RMCRI) from the local 
medical community. Patients were then screened for the cancer exercise rehabilitation 
program through RMCRI at the University of Northern Colorado to establish eligibility 
for the study. The inclusion criteria for this study consisted of: 1) must be at least 18 
years of age; 2) have been diagnosed with cancer; 3) have received chemotherapy 
treatment for cancer in the past or currently be undergoing chemotherapy treatment; 4) 
must have been experiencing self-reported neuropathy in either hands or feet; 5) have had 
no serious co-morbidities such as diabetes; and 6) been cleared by a physician for 
exercise. Exclusion criteria for this study consisted of: 1) diagnosis of Type I or Type II 
diabetes; 2) past or present alcohol abuse or substance abuse; 3) history of central 
nervous system dysfunction prior to a cancer diagnosis; or 4) currently receiving 
pharmacological interventions for CIPN or other forms of intervention for the 
management of CIPN.  Participants who met these criteria and were willing to participate 
were assigned to a specific training phase and exercise intervention following the initial 
assessment. The participants were informed of the nature of the exercise intervention and 





the appropriate weights and intensities, the initial assessment values were used. After the 
participants were informed and understood the study and the protocols, they signed a 
copy of the informed consent, which was approved by the University of Northern 
Colorado Institutional Review Board (see Appendix 1). As per the directions on the 
informed consent, a copy was also made available for them to keep.  
Assessment 
	  
Physiological measurements were evaluated during the initial and post 
assessment. These measures included balance, cardiovascular endurance, pulmonary 
function, body composition, functional movement, flexibility, and muscular strength and 
endurance.  During both the pre and post assessments, a heart rate monitor (Polar, Inc. 
Lake Success, NY) was worn by each participant at all times to monitor heart rate 
response to exercise. Blood pressure and oxygen saturation were also measured at the 
beginning and end of the assessment with a sphygmomanometer and pulse oximeter, 
respectively.  
Cardiovascular Assessment 
Cardiovascular endurance was evaluated using RMCRI’s VO2peak treadmill test. 
This protocol has been found to be more accurate and appropriate for cancer survivors 
due to the sensitivity of the population (Shackelford, Brown, Lalonde, Hydock, & 
Schneider, 2012).  The objective of the test is to allow the participant to reach self-
perceived maximal exhaustion or fatigue, and the highest measurement of oxygen 
consumption was recorded. For RMCRI’s treadmill protocol, heart rate and oxygen 
saturation were recorded and obtained at the end of each minute/stage, blood pressure and 





increased at the end of each minute. Termination of the test occurred when the participant 
reached volitional fatigue, asked to stop, or the Cancer Exercise Specialist felt the test 
needed to be terminated due predetermined termination criteria. The criteria for 
terminating the VO2peak test included: drop in systolic blood pressure of more than 10 
mmHg, heart rate does not increase with increased intensity, diastolic blood pressure 
fluctuates more than 10 mmHg from baseline, or oxygen saturation dropped below 80 on 
the pulse oximeter (Arena, 2014). The time in which VO2peak was established was 
recorded in standard and decimal form, as well as whether the participant was running or 
walking and if handrails were used. VO2 values were obtained utilizing ACSM metabolic 
equations.  
Strength and Muscular Endurance 
 Strength was assessed using the estimated 1-repetition maximum test along with 
the Brzycki equation (Brzycki, 1993). This information allowed the Cancer Exercise 
Specialist to write an accurate exercise prescription and progress the participant 
appropriately. Muscular endurance was evaluated using the handgrip test (Mathiowetz, 
Weber, Volland, & Kashman, 1984), core/plank test, and the chair squat test, which 
indicated the level of muscular fatigue the participant experienced. These tests also 
helped to indicate which muscle groups would need more endurance training through the 
intervention. 
Estimated 1-Repetiton Max Assessment. Muscular strength was estimated via 
the Brzycki equation using an estimated 1-repetition max (est. 1-RM) test. The exercises 
assessed were the latissimus dorsi (lat) pull-down, shoulder press, chest press, seated row, 





(Cybex International., Inc., Medway, MA). The researchers demonstrated how to perform 
each exercise and the seat was adjusted to an estimate of proper fit for the participant. 
With an appropriate weight, the participant was instructed to perform five warm-up 
repetitions. Next, a starting weight was selected and each participant was asked to 
perform repetitions until told to stop.  If a participant reached ten repetitions, the set was 
stopped automatically.  An RPE was asked of the participant after every set and then the 
weight was adjusted accordingly. If ten repetitions were reached during the second set, 
the participant would move on to another machine and then repeat the same machine later 
during the assessment.   
Handgrip Strength Assessment. Handgrip strength was evaluated using a 
handgrip dynamometer (Takei Scientific Instruments Co., LTD., Niigata City, Japan). 
The handgrip size was adjusted accordingly for the participant. The participant was then 
instructed to hold the dynamometer by his or her side with the dial facing away from the 
body, and to squeeze the dynamometer as hard as possible without moving the arm. 
Three trials were administered for each hand, alternating hands after every attempt, and 
then the highest values were recorded.  
Core Muscular Endurance Assessment. Core muscular endurance was assessed 
using the plank test. For the plank test, the participant began in a neutral position on his 
or her hands and knees. Each participant was then instructed to assume the plank 
position, with his or her forearms on the floor in front of him or her, while keeping his or 
her hips in line with his or her spine and were asked to hold the position as long as 





Chair Squat Test. For the chair squat test, the researchers showed the participant 
the proper form for doing a squat onto a chair. A chair was then positioned behind the 
participant and the participant was instructed to cross his or her arms and squat down into 
the chair so that their buttocks touched the seat for a brief moment, and then return to 
standing. The participant was instructed to perform as many squats as possible until 
fatigue or until 50 repetitions were completed. Values were then recorded.   
Chemotherapy-Induced Peripheral  
Neuropathy Assessment 
 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) was evaluated in each 
participant to look for changes prior to and after the 12-week intervention of strength, 
aerobic and flexibility training. CIPN was evaluated using the Semmes-Weinstein 
Monofilament Test (SWMT) (Feng, Schlösser, & Sumpio, 2011; Tan, 2010; Feng et al., 
2009; Kamei et al., 2005; Leonard et al., 2004; Lee et al., 2003; Kochman et al., 2002; 
Olaleye et al., 2001; Mueller, 1996; Kumar et al., 1991; Grunfield, 1988). A total of ten 
sites were evaluated using the 5.07/10g monofilament and the 4.17/1 monofilament on 
both the feet and hands of the participant, depending on the location of the neuropathy. 
The ten sites used to assess the foot were the dorsal mid-foot, the medial and lateral mid-
foot, the calcaneus, and the plantar aspect of the foot, including the first, third, and fifth 
digits, as well as the first, third, and fifth metatarsal heads (Figure 1). Both the 4.17 and 
5.07 monofilament have been suggested to be used to identify patients at risk with 
peripheral neuropathy (Lee et al., 2003; Mueller, 1996; Kumar et al., 1991). The tests 
were performed bilaterally. Participants who had self-reported symptoms of CIPN in the 
feet were instructed to lie supine, with their toes pointing up, and were blindfolded. The 





monofilament.  The researcher did not inform the participant when the monofilament 
would be applied to the skin and the sites were randomly tested. The filament was 
pressed slowly onto the test site and then bowed for 1.5 seconds. The participant was 
instructed to respond, “Yes,” whenever the participant recognized that he or she was  
being touched by the filament and on which side of the body. Participants who could not 
detect the 4.17 or 5.07 monofilament on a specific site were classified as having a loss of 
protective sensation in that specific site. To assess for neuropathy of the hand, a ten-site 
method was used. The sites were: (1) the medial surface of the palm, (2) first medial 
metacarpal head, (3-5) first, third, and fifth metacarpophalangeal joint, (6-8) first, third, 
and fifth distal phalanx head, and (9-10) the third and fifth distal metacarpal head (Van 
Brakel et al., 2003; Nunes, de Oliveira, Aruin, & dos Santos, 2012). (Figure 2). The same 
monofilaments were used for the hand test as for the foot test. For this test, the participant 
was instructed to lie supine, extend his or her arm out laterally, palm face up, and were 
blindfolded. Participants were also blinded to the test in that they were not able to watch 
the test being performed on them. The test would then be administered the same way as 
the foot assessment and one insensate site would put the participant at risk for neuropathy 
(Tan, 2010).  Quick application and bouncing of the filament were avoided.  To help 
ensure accuracy, the same two evaluators were used for every SWMT test. Using a 
conservative approach for this study, it was best thought to include a site pertaining to 
each nerve that runs through either the hand or foot. Also, because there is no clear 
evidence on how to score a SWMT, any one insensate site was considered to be an 






Phase Training of Cancer Rehabilitation 
 
The exercise intervention took place at the Rocky Mountain Cancer Rehabilitation 
Institute (RMCRI) on the University of Northern Colorado (UNC) campus in Greeley, 
Colorado.  RMCRI is a nationally recognized cancer rehabilitation center that maintains 
consistent referrals of cancer patients who experience treatment-related side effects. 
Physiological data was recorded by UNC graduate and undergraduate students in the 
exercise physiology department.  RMCRI utilizes a Phase training system to confirm that 
the five basic principles of exercise are being met. These five principles include overload, 
specificity, individuality, diminishing return, and reversibility. The Phase system allows 
for individuality of each participant based on stage of cancer, treatment types, and time 
since treatment. It also allows for progression at appropriate intensities according to the 
individual.  
The RMCRI phase program consists of four Phases. Phase One consists of 
participants who are receiving treatment during the exercise intervention. The main goal 
of this Phase is to attenuate the deleterious effects of chemotherapy and radiation 
treatments. The participants who are in this Phase may not see improvement, but there 
should not be any declination in initial values. The exercise intensity established for this 
phase is 30-45% of a participant’s heart rate reserve (HRR) and est. 1-RM. 
Cardiovascular and muscular improvement might only be 0-5% for this phase, and 
participants should be reporting RPE values from 1-3. The participant remains in Phase 
One until he or she has fully completed his or her treatment regimen. 
Phase Two of the training program is intended for participants who have 





treatment, or participants who are new to the RMCRI program and have not undergone 
chemotherapy or radiation. The goal of Phase Two is to build a foundational base of 
exercise using corrective and functional training. The training intensity established for 
this phase is 40%-60% of the participant’s HRR and est. 1-RM, and the participant 
should be reporting RPE’s of 3-6. Cardiovascular and muscular improvement for this 
Phase may increase by 10-20%. The time duration of this phase is 12 weeks.  
Phase Three of RMCRI’s phase training program is intended for participants who 
have graduated from Phase Two. The goal of this phase is to continue to improve 
physiological and psychological variables beyond baseline measures and should be able 
to progress to functional health or become “apparently healthy.” Another goal of this 
Phase is to instruct the participant how to exercise without the help of a trainer and for 
the participant to become knowledgeable about exercises. The exercise intensity 
established for this phase is considered moderate-to-high at 60%-85% of the participant’s 
HRR and est. 1-RM. Cardiovascular improvements may increase by 5-15% for this 
phase, while muscular improvements may improve by 30-50%. The period for this Phase 
is three months.  
Phase Four of RMCRI’s phase program is for participants who have graduated 
from Phase Three and could be considered “apparently healthy.”  The goal of this phase 
is to continue improving physiological and psychological measures. The exercise 
intensity established for this phase is 65%-95% of a participant’s HRR and est. 1-RM, 
and the timeline is limitless for this Phase. Clients who are in this Phase are now healthy 
and knowledgeable enough to exercise on their own, in a group model, or continue with 





5% increments for this phase. For the purpose of this study, only participants in Phases 
One and Two will be used. 
Exercise Intervention 
	  
The aerobic portion of the intervention was conducted on a treadmill 
(Trackmaster, city etc. or MedTrack CR60, city etc.), cycle ergometer (Life Cycle 8500, 
city etc.; Life Cycle 9500E, city etc.; SciFit, city), and/or NuStep (Biodex), Aerobic 
exercise was performed for 20 minutes between 30% and 60% of the participant’s HRR 
depending on the Phase of the RMCRI program the participant was enrolled into. Each 
participant was prescribed to either maintain his or her cardiovascular and muscular 
strength baseline measures or increase from 5%-20% also depending on his or her phase.  
The muscular strength portion of the intervention was conducted with free 
weights, Cybex Fitness Machines, and/or body weight. The muscular strength 
intervention was also performed at 30% to 60% of the participant’s est. 1-RM depending 
on the Phase of the RMCRI program the participant was assigned. The participant either 
maintained muscular strength or increased it by 10%-50%. This portion of the 
intervention lasted 30 minutes. During the muscular strength training intervention, 
balance was also included. In order to incorporate balance, the participant may have been 
asked to perform an exercise on a stability ball, BOSU, foam pad, or textured balance 
pods.  
 The flexibility portion of the intervention lasted ten minutes in length and was 
conducted at the end of the training session. Any muscle groups used during the strength 
portion of the training intervention were stretched accordingly and ranges of motion 





NASM squat test results. Equipment that may have been used for stretching included 
rope pulleys, a ROM wheel harnessed to the wall, ropes, or gliding disks.  
Statistical Analysis 
	  
 Preliminary descriptive and data frequency analyses were run to represent the raw 
data visually.  A power analysis was run initially to determine appropriate sample size. A 
Wilk’s Lambda multivariate analysis of variance (MANOVA) test was run on the pre, 
mid, and post CIPN assessment scores to evaluate any changes due to the exercise 
intervention. Individual MANOVA’s were run for the 4.17 and 5.07 monofilament tests. 
A paired sample T-test was run on physiological assessment pre- and post- data and 
psychological assessment data to evaluate any changes due to the exercise intervention. 














 Participant characteristics are shown in Table 1. For the purpose of this 
observation, this study included 10 participants (6 females, 4 males). Ten out of thirteen 
eligible participants completed the 12-week exercise intervention along with pre-, mid-, 
and post- assessments. Two subjects that were not able to complete the study dropped out 
for personal reasons and one subject passed away during the study. Each participant that 
completed the training study was able to complete 36 sessions. If a participant had to 
cancel a session for personal reasons, there were no more than 10 days between the next 
training sessions in order to sustain training effects. All participants completed pre-, mid- 
and post- assessments. Cancer Exercise Specialists at the Rocky Mountain Cancer 
Rehabilitation Institute conducted the physical and psychological assessments. In 
addition, during the year and a half that this study took place, there were a total of two 
different assessors for the CIPN portion of the assessment.  
Table 1 
 Participant Characteristics 
N Weight (pounds) Height (inches) Age (years) 
12  171 ± 46  66 ± 4  62 ± 7 





Chemotherapy-Induced Peripheral Neuropathy  
Changes after Intervention 
 
 The Wilk’s Lambda Multivariate Test showed significant (P < .05) effects 
between all three levels for the 4.17 SWMT. Mauchly’s test of sphericity did not show 
significance (p > .05) of variance between groups. Results are presented in Table 2 
below. Figure 1 also shows a negative trend of the SWMT 4.17 cumulative scores over 
time. For the 5.07 SWMT, the Wilks Lambda Multivariate test showed no significant 
effects (p > .05) due to training. Mauchly’s test of sphericity did not show significance (p 
< .05) of variance between groups. Statistical results are presented in Table 2 below. 
Figure 2 shows a partial negative trend of SWMT 5.07 cumulative scores below.  
 
Table 2 
SWMT Significant Differences 
   p value Mauchly’s Test 
of Sphericity 
SWMT 4.17   .025 .576 
SWMT 5.07 .060 .957 
Note: Significant difference for SWMT 4.17 pre- to mid- to post; no significant 
differences were found for SWMT 5.07 tests pre- to mid- to post-; SWMT, Semmes 






Figure 1. 4.17 Semmes Weinstein Monofilament Scores Over Time. Values are 
composite scores from each participant; Average, average score on CIPN assessment; 










































Figure 2. 5.07 Semmes Weinstein Monofilament Scores Over Time. Values are 
composite scores from each participant; Average, average score on CIPN assessment; 
linear trend line is based on average scores; CIPN, chemotherapy-induced peripheral 
neuropathy;  
 
Strength Changes after Exercise  
Intervention 
 
 Paired Sample T-Tests showed some significant (p < .05) changes in strength pre 
to post assessment. Results for all strength assessments pre- to post are presented in Table 
3 below. Latissimus pull-down, shoulder press, chest press, leg curl, and leg press all 
showed significant changes. Row and leg extension did not show significant changes. 
Functional strength showed some significant (p < .05) changes in strength pre to post. 





















Both right and left hand grip tests showed significant changes; however, the chair test and 
plank test did not show significant changes. 
Table 3 








89 ± 35 100 ± 28 .021* 
Shoulder Press 40 ± 19 54 ± 23 .014* 
Chest Press 64 ± 28 84 ± 38 .000* 
Row 71 ± 26 92 ± 34 .141 
Leg Curl 79 ± 28 99 ± 23 .030* 
Leg Extension 83 ± 41 111 ± 46 .085 
Leg Press 158 ± 45 206 ± 64 .002* 
Note: Weights are means ± standard deviation in pounds; *significance set at p < .05. 
 
Table 4 
Functional Strength Values Pre- and Post- Intervention 
Exercise Pre  Post p value 
Chair Test (reps) 20 ± 14  28 reps ± 10 .148 
Plank Test (reps) 41 ± 23  48 sec ± 20 .450 
Handgrip R (kg) 22 ± 10 27 kg ± 12 .000* 
Handgrip L (kg) 21 ± 11 24 kg ± 11 .003* 
Note: Values are means ± standard deviation; Reps, repetitions; sec, seconds; kg, 
kilograms; *significantly different at p < .05. 
 
Aerobic Changes after Exercise Intervention 
 
 There were significant (p < .05) main effects observed for Paired T-Test analysis 
for VO2peak . Aerobic physiological changes from pre- to post- training assessments are 







 VO2peak Pre- and Post- Intervention 
 Pre Post p value 
VO2peak 19.07 ± 3.4 24.1 ± 7.7 .014* 
Note: All values are ml/kg/min-1; Values are means + standard deviation; *significantly 














The Wilk’s Lambda Multivariate test was able to also show significant 
differences between pre- and post- data for VO2peak, strength values, and functional 
strength values. It was expected that significant differences would be present between the 
pre and post assessments. In fact, VO2peak increased significantly due to the aerobic 
exercise intervention.  All strength values increased significantly with the exception of 
the 1-RM row, 1-RM leg extension, chair squat test, and plank test. This indicates that 
exercise adaptations did occur and the reduction in CIPN symptoms could be related to 
the exercise adaptations. It could also be concluded from the results that exercise had a 
beneficial effect on CIPN symptoms. Research has supported the assumption that 
exercise stimulates endoneurial blood flow and mitochondrial protein synthesis and 
glycolysis which both have the ability to generate energy (Tofthagen et al., 2012). 
Exercise could ultimately increase the supply of blood, oxygen, and other essential 
nutrients to the mitochondria, and then to the peripheral nerves, which could result in 
fewer neuropathic symptoms (Tofthagen et al., 2012). Exercise also has been suggested 
to enhance nerve re-innervation as well as an increase in neurotropic factors within the 
peripheral nerves (Wilkes, 2007; Sabatier et al., 2008). Both of these have the possibility 





possibly be accurate. In addition, the theory that exercise can benefit peripheral nerve 
damage is in agreement with Sabatier et al., 2008 and Kluding et. al., 2012.  
The reduction in 4.17 SWMT scores from pre- to post- and symptoms supports 
the theory that exercise could serve as an alternative form of treatment in the 
management of CIPN.  However, it is unknown from this study whether or not the 
aerobic exercise, strength training, or combination of the two was more beneficial. Since 
both aerobic and strength training have been shown to improve side effects of cancer 
treatments, the researchers did not want to disadvantage any participants by only having 
them participate in one modality. Further research will need to be conducted to determine 
if one modality has a greater effect than the other on CIPN symptoms. However, for the 
purpose of this study, the combination of the two suggested the greatest benefit in 
reduction of CIPN symptoms.  
 Future research should also include analyzing different modalities that could 
increase blood flow and peripheral vasodilation to the nerves, such as laser treatments or 
heat treatments. However, patients who experience CIPN can have difficulty in sensing 
temperature in the affected areas (Wolf et al., 2008; Wilkes, 2007). Some subjects may 
sense temperatures as extremes, and some subjects may not feel any temperature change 
at all. What would be warm to an apparently healthy person may present as a burning 
sensation to a person experiencing CIPN. Also, if the temperature is too hot, the subject 
may not be able to sense that it is too hot.  Thus, temperature would have to be closely 
monitored.  
Another explanation to the reduction in 4.17/1g SWMT scores is a cessation of 





stated earlier, CIPN is dose dependent, indicating that once a subject stops receiving 
treatment, his or her symptoms may disappear. This is not always the case, however, as 
each subject is different. In order to control for this, future research will need to include a 
control group.  
 ` The Wilk’s Lambda Multivariate test was able to show significant differences 
between pre-, mid-, and post- CIPN assessment scores for the 4.17/1g SWMT but not for 
the 5.07/10g SWMT. These two tests differ in that the 4.17/1g SWMT is used to detect a 
diminishing protective sensation and the 5.07/10g SWMT is used to detect the loss of 
protective sensation (Feng et al., 2009; Tan, 2010; Lee et al., 2003; Olaleye et al., 2001; 
Kamei et al., 2005; Leonard et al., 2004; Kumar et al., 1991; Lee et al., 2003; Callahan et 
al., 1995; Kumar et al., 1991). Thus, the 4.17/1g SWMT detects for the onset of 
neuropathy, while the 5.07/10g SWMT detects for a more progressive form of 
neuropathy. Paresthesia and numbness are sometimes considered earlier signs of 
neuropathy because the sensory neurons and axons that transmit these signals are 
unmyelinated, so they are affected sooner than myelinated fibers by the chemotherapy 
agents (Malik & Stillman, 2008). As CIPN progresses, all sensation would cease in the 
hands and feet (Malik & Stillman, 2008). This could suggest that the subjects from this 
study were still in the early stages of CIPN, which would indicate why the 5.07/10g 
SWMT did not significantly report changes in CIPN. The 4.17/1g SWMT may be more 
useful in the early detection of peripheral neuropathy and may be more useful for 
detecting CIPN. All of the subjects had patient reported symptoms of CIPN prior to entry 
into the study. However, some subjects were still sensate to the 5.07/10g SWMT, but 





have complete loss of protective sensation; thus, they could still feel the 5.07/10g 
SWMT. Thus, if a patient reports he or she is feeling signs of neuropathy, it is possible he 
or she would still be sensate to the 5.07/10g monofilament. It could conclude that all the 
subjects were only experiencing a diminished loss of protective sensation and CIPN is 
more likely to be diminishing in sensation rather than a total loss of protective sensation. 
This could also conclude that 4.17g/1g monofilament is a more accurate measurement for 
CIPN because it tests for the diminished sensation rather than total loss.   
 The 5.07/10g SWMT test did not present with significant differences from pre- to 
mid- to post- CIPN assessment scores. This could be mainly due to the fact that current 
research supports the 5.07/10g SWMT for diabetic peripheral neuropathy, but not for 
CIPN. Since the cellular mechanisms between the two conditions are different, the caliber 
of symptoms may also be different. The general symptoms between the two are similar; 
however, DPN is speculated to be caused by a metabolic issue, while CIPN is said to be 
caused by toxic agents (Schloss et al., 2013; Kluding et al., 2012; Wolf et al., 2008; 
Balducci et al., 2006). The results from the current study are not in agreement with 
current research (Feng et al., 2009; Tan, 2010; Lee et al., 2003; Olaleye et al., 2001; 
Kumar et al., 1991). However, many of these studies were assessing the use of the 
5.07/10g SWMT on diabetic peripheral neuropathy. The 5.07/10g SWMT may not be a 
useful assessment tool for CIPN and needs further research. DPN is due to a 
hyperglycemic environment, ultimately (Head, 2006). DPN can be possibly resolved by 
maintaining glycemic control (Singh, Armstrong, & Lipsky, 2005; Kluding et al., 2012; 
Braunstein, 2001). CIPN is due to a toxic agent damaging part of the nerve and 





(Quasthoff & Hartung 2002). Currently, the only alleviating agent for CIPN is cessation 
of chemotherapy treatment (Hausheer et al., 2006; Quasthoff & Hartung 2002; Wilkes, 
2007). However, this is not always an option for many people who are receiving 
chemotherapy. Some studies have found vitamins to be helpful, but nothing that 
demonstrated substantial efficacy (Hausheer et al., 2006; Quasthoff & Hartung 2002; 
Speck et al., 2012). The results from the current study suggest that exercise could be 
beneficial in alleviating symptoms of CIPN. 
 The results of this study indicate that exercise may an effective and safe treatment 
in the management of CIPN symptoms. Prior research has examined the effects of 
vitamins on CIPN symptoms, but no conclusive results were obtained. Heat therapy could 
also be beneficial for patients with CIPN; however, there is a higher risk factor for burns 
or injury due to the nature of the symptoms of CIPN. Not only could exercise alleviate 
CIPN symptoms, but it has shown improvement for other side effects that could develop 
due to chemotherapy treatments as well.  
Conclusion 
 To our knowledge, there has been very little research on the effects of aerobic 
training and strength training on CIPN symptoms. Results from the current study reported 
significant differences between pre-, mid-, and post- 4.17 SWMT CIPN assessment 
scores, as well as other important outcomes occurred. First, aerobic and strength training 
were beneficial to paresthesia symptoms associated with CIPN. Exercise has the ability to 
increase blood flow and nutrient flow to peripheral nerves, which could help repair any 
damage that occurred (Tofthagen et al., 2012; Sabatier et al., 2008; Wilkes, 2007; 





for assessing neuropathy in cancer patients than other calibers of the SWMT. All of the 
subjects assessed had patient-reported symptoms of neuropathy; however, the 5.07/10g 
SWMT, which previous research supported, did not significantly detect changes in CIPN 
score. More research and validation is needed for this theory. Lastly, exercise should be 
included in any post-cancer treatment rehab because it can attenuate many side effects of 
treatment. Along with being beneficial for the symptom management of CIPN, it can also 
lessen fatigue and depression, increase VO2peak, and increase whole body strength. 
Previous studies have documented exercise as beneficial to anyone who is combating 
cancer treatments, but to date, there is not much research examining the effects of aerobic 
and strength training on CIPN.   
Limitations 
	  
 Although the need for more research in this area was a strong point for this study, 
several limitations did occur. The small sample size was a major limitation to this study. 
The original power analysis suggested a sample size of fifteen participants. However, due 
to Cancer Exercise Specialist availability and scheduling, RMCRI was not able to accept 
as many new patients as preferred. Time frame was also a limitation to this study. CIPN 
was only assessed over a 12-week period. Many participants still had some symptoms of 
CIPN at the end of their intervention. A major limitation to this study was the lack of a 
control group. Since research has shown to benefit patients who are receiving cancer 
treatment, the researchers did not want to disadvantage some in order to create a control 
group. It is also known that CIPN is dose-dependent. This means that if a subject were to 
terminate his or her chemotherapy, it is possible that CIPN symptoms would start to 





control group to test for this assumption. A longer time period is needed to further 
evaluate the effects of exercise. Along with time frame, another limitation is when the 
patient stopped receiving his or her chemotherapy treatment. Since CIPN is dose 
dependent, it is possible that a patient’s symptoms will gradually start to lessen after he or 
she receives his or her final dose of chemotherapy.  Another major limitation was the lack 
of knowledge. There is very little research regarding CIPN and exercise to date. Due to 
this, researchers had to rely on information regarding diabetic peripheral neuropathy. 
However, the two conditions are similar, but the mechanism of onset is different; thus, 
treatment and management may be different as well. More research needs to be 
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  Stage    Speed (mph) 




with VO2 Peak 
Calculation 
Estimated VO2 Peak  
(mL/kg/min) Estimated VO2 Peak (Handrails) 
0 1.0 0 1:00-1:59 6.2 (walk) 6.2 (walk) 
1 1.5 0 2:00-2:59 7.5 (walk) 7.5 (walk) 
2 2.0 0 3:00-3:59 8.9 (walk) 8.9 (walk) 
3 2.5 0 4:00-4:59 10.2 (walk) 10.2 (walk) 
4 2.5 2 5:00-5:59 12.6 (walk) 12.1 (walk) 
5 3.0 2 6:00-6:59 14.4 (walk) 13.4 (walk) 
6 3.3 3 7:00-7:59 17.1 (walk) 15.2 (walk) 
7 3.4 4 8:00-8:59 19.2(walk) 16.6 (walk) 
8 3.5 5 9:00-9:59 21.3(walk) 18.1 (walk) 
9 3.6 6 10:00-10:59 28.0 (run) 23.6 (walk) 22.8 (run) 19.7 (walk) 
10 3.7 7 11:00-11:59 29.6 (run) 25.9 (walk) 23.9 (run) 21.3 (walk) 
11 3.8 8 12:00-12:59 31.2 (run) 28.3 (walk) 25.0 (run) 23.0 (walk) 
12 3.9 9 13:00-13:59 32.9 (run) 30.9 (walk) 26.1 (run) 24.8 (walk) 
13 4.0 10 14:00-14.59 34.6 (run) 33.5 (walk) 27.3 (run) 26.6 (walk) 
14 4.1 11 15:00-15:59 36.4 (run) 36.2 (walk) 28.6 (run) 28.5 (walk) 
15 4.2 12 16:00-16:59 38.2 (run) 39.1 (walk) 29.8 (run) 30.4 (walk) 
16 4.3 13 17:00-17:59 40.0 (run) 42.0 (walk) 31.1 (run) 32.5 (walk) 
17 4.4 14 18:00-18:59 41.9 (run) 45.0 (walk) 32.4 (run) 34.6 (walk) 
18 4.5 15 19:00-19:51 43.9 (run) 48.1 (walk) 33.8 (run) 36.7 (walk) 
19 4.6 16 20:00-20:59 45.9 (run) 51.3 (walk) 35.2 (run) 39.0 (walk) 
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